Related Experiment Video
Updated: Jul 7, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Late fatal recurrence in gefitinib-treated NSCLC patients
Kunihiko Miyazaki1, Tetsushi Ano, Kensuke Nakazawa
1Division of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Japan.
Abstract:
Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor, which blocks signal transduction pathways implicated in proliferation and survival of cancer cells. Long-term survival in patients with metastatic non-small-cell lung carcinoma (NSCLC) treated with gefitinib has recently been reported. We showed herein two cases of fatal rapid recurrence after a long-term disease control by gefitinib. The biology of fatal aggressive recurrence of gefitinib-treated NSCLC is not well characterized. Regardless of the mechanism, however, physicians treating patients with gefitinib should be alert to the possibility of fatal rapid recurrence after a long-term disease control by this drug.
Insights
Gefitinib can lead to long-term control of non-small-cell lung cancer (NSCLC). However, some patients experience fatal rapid recurrence after initial disease control with gefitinib.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting cancer cell proliferation and survival pathways.
- Recent reports indicate long-term survival for metastatic non-small-cell lung carcinoma (NSCLC) patients treated with gefitinib.
- The mechanisms underlying aggressive recurrence in gefitinib-treated NSCLC require further investigation.
Observation:
- This report details two cases of fatal rapid recurrence in NSCLC patients.
- These recurrences occurred after a prolonged period of disease control achieved with gefitinib therapy.
- The aggressive nature of these late recurrences was unexpected.
Findings:
- Fatal rapid recurrence can occur even after long-term disease control with gefitinib.
- The biological basis for this aggressive recurrence pattern in NSCLC is not well understood.
- These cases highlight a potential, albeit rare, adverse outcome of gefitinib treatment.
Implications:
- Physicians must remain vigilant for the possibility of rapid, fatal recurrence in NSCLC patients on long-term gefitinib therapy.
- Awareness of this phenomenon is crucial for patient management and monitoring.
- Further research into the biology of gefitinib resistance and recurrence is warranted.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017